— Know what they know.
Not Investment Advice

ICAD NASDAQ

iCAD, Inc.
1W: -0.3% 1M: +1.0% 3M: +100.5% 1Y: +209.6% 3Y: -8.5% 5Y: -58.8%
$3.87
Last traded 2025-07-17 — delisted
NASDAQ · Healthcare · Medical - Devices · $106.3M mcap · 26M float · 3.06% daily turnover · Short 32% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$106.3M
52W Range1.19-4.01
Volume190,127
Avg Volume789,055
Beta1.40
Dividend—
Analyst Ratings
8 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEODana R. Brown
Employees66
SectorHealthcare
IndustryMedical - Devices
IPO Date1984-12-13
98 Spit Brook Road
Nashua, NH 03062
US
603 882 5200
About iCAD, Inc.

iCAD, Inc. specializes in delivering advanced solutions for cancer management, encompassing sophisticated image analysis tools, streamlined workflow optimization, and targeted radiation therapy. While primarily operating in the United States, the company also maintains a significant international presence. Its operations are organized into two principal divisions: Cancer Detection and Cancer Therapy. In the Cancer Detection segment, iCAD provides a range of innovative technologies. This includes the PowerLook platform, which serves as a central host for artificial intelligence algorithms and facilitates seamless communication between imaging acquisition devices, storage systems, and review platforms. Key diagnostic offerings feature SecondLook, a machine learning-driven algorithm designed to examine 2D full-field digital mammography images for identifying and marking suspicious masses and calcifications. Additionally, the company offers automated solutions for consistent and standardized assessment of breast density. Its portfolio further extends to ProFound AI, a deep-learning algorithm adept at detecting malignant soft-tissue densities and calcifications within digital breast tomosynthesis, and ProFound AI Risk, a tool that provides breast cancer risk estimation derived from screening mammograms. Magnetic resonance imaging (MRI) applications are also available for detecting breast and prostate cancer, along with VeraLook, a solution supporting the identification of colonic polyps in conjunction with CT Colonography. The Cancer Therapy division features the Xoft Axxent electronic brachytherapy systems. These systems are employed in the treatment of early-stage breast, non-melanoma skin, and gynecological cancers. Their clientele is diverse, spanning university research centers, community hospitals, specialized cancer care clinics, veterinary facilities, and dermatology practices. iCAD distributes its products through multiple channels, utilizing its own direct sales organizations, as well as collaborating with original equipment manufacturer (OEM) partners, various distributors, technology platform partners, and resellers. The company also has a global footprint, exporting its advanced technologies to regions including Europe, Taiwan, Canada, China, and other international markets. Originally established in 1984 under the name Howtek, Inc., the company was rebranded as iCAD, Inc. in June 2002. Its corporate headquarters are located in Nashua, New Hampshire.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Hricak Hedvig D-Return 40,000 $1.36 2025-07-17
Hricak Hedvig D-Return 6,641 $3.69 2025-07-17
Hricak Hedvig D-Return 5,415 $1.52 2025-07-17
Hricak Hedvig D-Return 30,000 $2.06 2025-07-17
Go Jonathan D-Return 25,000 $4.37 2025-07-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms